UPDATE : Wednesday, July 15, 2020
Celltrion unveils long-term P3 trial results for Truxima in US
Celltrion said that it has presented the long-term follow-up results of its...
by Lee Han-soo  |  2019-12-09 10:36
Celltrion 1st Korean biopharmaceutical firm to achieve $1-billion exports
Celltrion Healthcare said that it has become the first local biopharmaceuti...
by Lee Han-soo  |  2019-12-05 15:04
Alteogen inks licensing-out deal for SC injection formulation technology
Alteogen, a biotech firm, said it has successfully concluded a deal to make...
by Jeong Sae-im  |  2019-12-02 15:25
Kolon Life Science’s research head arrested for false Invossa data
A Seoul court issued an arrest warrant for an executive at Kolon Life Scien...
by Jeong Sae-im  |  2019-11-28 11:18
FDA begins to review Samsung Bioepis' anticancer biosimilar application
Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis said tha...
by Lee Han-soo  |  2019-11-20 15:10
Vivozon’s acquisition of Lumimicro may aim at backdoor listing
Vivozon, a privately held biopharmaceutical firm on the over-the-counter (O...
by Jeong Sae-im  |  2019-11-20 14:44
ABL Bio, Genscript to cooperate on bispecific antibodies
ABL Bio said that it would co-develop new bispecific antibodies with Genscr...
by Lee Han-soo  |  2019-11-19 17:18
Will Biogen be 1st to get FDA nod for Alzheimer’s drug?
Biogen recently unveiled the new results of studies on aducanumab, an inves...
by Kim Yun-mi  |  2019-11-14 11:23
How can Korean drugmakers enter Europe successfully?
Officials from the Korea Pharmaceutical and Bio-Pharma Manufacturers Associ...
by Jeong Sae-im  |  2019-11-13 15:22
Samsung Bioepis expects ₩1 trillion biosimilar sales this year
Samsung Bioepis said it was confident of achieving 1 trillion won ($855.8 m...
by Jeong Sae-im  |  2019-11-13 15:21
[News Focus] ‘FDA could allow resumption of Invossa trial’
Amid the prosecution’s probe into Kolon Life Science’s osteoarthritis gene ...
by Jeong Sae-im  |  2019-11-12 15:48
Celltrion marks robust Q3 sales
Celltrion said that it has recorded sales of 289.1 billion won ($249 millio...
by Lee Han-soo  |  2019-11-07 14:03
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates
Samsung Bioepis said the company would strengthen its partnership with Biog...
by Lee Han-soo  |  2019-11-07 11:16
Court rejects arrest warrant for 2 Kolon execs
A local court has refused to issue an arrest warrant against two executives...
by Jeong Sae-im  |  2019-11-05 13:54
Samsung BioLogics to make Ichnos Sciences’ atopic dermatitis treatment
Samsung Biologics said that it has signed a contract with Ichnos Sciences t...
by Lee Han-soo  |  2019-11-05 12:47
Prosecutors seek to arrest 2 Kolon execs for false Invossa data
Prosecutors have sought arrest warrant for two executives of Kolon Life Sci...
by Jeong Sae-im  |  2019-10-31 15:34
Syntekabio passes prior review for Kosdaq listing
Syntekabio, a new drug developer using artificial intelligence (AI)-based g...
by Jeong Sae-im  |  2019-10-31 13:27
Prosecution seeks jail term for Samsung execs for destroying evidence
Prosecutors demanded jail terms of one to four years for Samsung executives...
by Jeong Sae-im  |  2019-10-29 13:10
KangStem Biotech changes strategy for atopic dermatitis drug
KangStem Biotech changed its strategy for Furestem-AD, an investigational s...
by Jeong Sae-im  |  2019-10-28 15:34
Bridge Biotherapeutics passes preliminary review for Kosdaq listing
Bridge Biotherapeutics has passed the regulatory agency’s preliminary revie...
by Jeong Sae-im  |  2019-10-25 15:05
Back to Top